Table 3.

Associations between marker protein expression and clinicopathological parameters

Variable	No. of cases	AGR2		P	KRT5		P
		No. of pos. (%)	No. of neg. (%)		No. of pos. (%)	No. of neg. (%)
Patient age
<60 years	116	50 (43.1%)	66 (56.9%)	0.196	60 (51.7%)	56 (48.3%)	0.548
≥60 years	72	38 (52.8%)	34 (47.2%)		34 (47.2%)	38 (57.8%)
Gender
Male	136	46 (33.8%)	90 (66.2%)	<0.001	84 (61.8%)	52 (38.2%)	<0.001
Female	52	42 (80.8%)	10 (19.2%)		10 (19.2%)	42 (80.8%)
Smoking history
Yes	125	40 (32.0%)	85 (68.0%)	<0.001	78 (62.4%)	47 (38.6%)	<0.001
No	63	48 (76.2%)	15 (23.8%)		16 (25.4%)	47 (74.6%)
Family history
Yes	38	16 (42.1%)	22 (57.9%)	0.515	20 (52.6%)	18 (47.4%)	0.716
No	150	72 (48.0%)	78 (52.0%)		74 (49.3%)	76 (50.7%)
Differentiation
Well-differentiated	47	40 (85.1%)	7 (14.9%)	<0.001	6 (12.8%)	41 (87.2%)	<0.001
Moderately or poorly differentiated	141	48 (34.0%)	93 (66.0%)		88 (62.4%)	53 (37.6%)
Histology
ADC	89	84 (94.4%)	5 (5.6%)	<0.001	1 (1.1%)	88 (98.9%)	<0.001
SCC	99	4 (4.0%)	95 (96.0%)		93 (93.9%)	6 (6.1%)
pT-status
pT1-2	165	78 (50.3%)	77 (49.7%)	0.036	73 (47.1%)	82 (52.9%)	0.084
pT3-4	33	10 (30.3%)	23 (69.7%)		21 (63.6%)	12 (36.4%)
pN-status
pN0-1	76	70 (92.1%)	6 (7.9%)	<0.001	4 (5.3%)	72 (94.7%)	<0.001
pN2-3	112	18 (16.1%)	94 (83.9%)		90 (80.4%)	22 (19.6%)
TNM stage
I-II	71	67 (94.4%)	4 (5.6%)	<0.001	1 (1.4%)	70 (98.6%)	<0.001
III-IV	117	21 (17.9%)	96 (82.1%)		93 (79.5%)	24 (20.5%)

Notes: Differences with P<0.05 were considered statistically significant.